Appl. No. 10/815,468
Amdt. dated July 20, 2006
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1641

PATENT

FEOEWED CENTRAL FAX GENTER JUL 2 0 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (currently amended): A microarray comprising a support having a plurality of 1 discrete regions having a biopolymer spotted thereon, wherein chemoselectively attached-to said 2 biopolymer in each of said regions is a ligand that can be the same or different from a ligand in 3 any other of said discrete regions, and wherein the concentration of said ligand in said discrete 4 regions is substantially normalized varies less than 50%. 5 2 (original): The microarray of claim 1, wherein said support is selected from the 1 group consisting of glass, polystyrene, PDVF membranes, nylon membranes, and polycarbonate 2 3 slides. 3 (original): The microarray of claim 1, wherein said biopolymer is a member 1 selected from the group consisting of oligosaccharides, proteins, polyketides, peptoids, 2 hydrogels, polylactates and polyurethanes. 3 4 (original): The microarray of claim 1, wherein said biopolymer is attached to 1 said support via noncovalent interactions. 2 5 (original): The microarray of claim 4, wherein said noncovalent interactions 1 are selected from the group consisting of hydrogen bonding, van der Waals interactions, 2 hydrophobic interactions, hydrophilic interactions and combinations thereof. 3 6 (original): The microarray of claim 1, wherein said biopolymer is attached to 1 2 said support via covalent interactions.

<u>PATENT</u>

Appl. No. 10/815,468
Amdt. dated July 20, 2006
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1641

1	7 (original): The microarray of claim 1, wherein said ligand is selected from the
	group consisting of amino acids, peptides, proteins, sugars, lipids, nucleic acids, small organic
2	compounds, pharmaceutical agents, candidate pharmaceutical agents, natural or synthetic
3	
4	antigens, and combinations thereof.
1	8 (canceled): The microarray of claim 1, wherein said ligand is attached to
2	said biopolymer via-chemoselective ligation.
	and the state of t
1	9 (original): The microarray of claim 1, wherein said biopolymer is agarose, and
2	said support is glass.
1	10 (withdrawn): The microarray of claim 1, wherein said biopolymer is human
2	serum albumin, and said support is polystyrene.
2	
1	11 (canceled): The microarray of claim 1, wherein the concentration in said
2	discrete regions varies less than 50%.
_	12 (previously presented): The microarray of claim 1, wherein the concentration
1	
2	in said discrete regions varies less than 20%.
1	13 (previously presented): The microarray of claim 1, wherein the concentration
2	in said discrete regions varies less than 5%.
1	14 (withdrawn): A method of producing a concentration-normalized ligand
2	array, said method comprising:
3	(a) forming a ligand-modified biopolymer by attaching a ligand to a
4	functionalized biopolymer via chemoselective ligation; and
5	(b) spotting an aliquot of said modified biopolymer mixture onto each of a
б	plurality of discrete regions on a solid support to produce a concentration-normalized ligand
7	array.

PATENT

Appl. No. 10/815,468 Amdt. dated July 20, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1641

1	15 (withdrawn): The method of claim 14, wherein said method further
2	comprises, prior to step (b), the following step:
3	(a)(i) combining said ligand-modified biopolymer with a biopolymer solution to
4	form a modified biopolymer mixture.
•	on a control of the c
1	16 (withdrawn): The method of claim 14, wherein said solid support is selected
2	from the group consisting of glass, polystyrene, PDVF membranes, nylon membranes, and
3	polycarbonate slides.
1	17 (withdrawn): The method of claim 14, wherein said aliquot is spotted onto
2	said solid support under conditions sufficient to form a gel-coated surface.
1	18 (withdrawn): The method of claim 14, wherein said biopolymer is a member
2	selected from the group consisting of oligosaccharides, proteins, polyketides, peptoids,
3	hydrogels, polylactates and polyurethanes.
1	19 (withdrawn): The method of claim 14, wherein said ligand is selected from
2	the group consisting of amino acids, peptides, proteins, sugars, lipids, nucleic acids, small
3	organic compounds, pharmaceutical agents, candidate pharmaceutical agents and combinations
4	thereof.
1	20 (withdrawn): The method of claim 14, wherein said ligand-modified
2	biopolymer is peptide-modified agarose and said solid support is glass.
1	21 (withdrawn): The method of claim 14, wherein said ligand-modified
2	biopolymer is peptide-modified human serum albumin and said solid support is polystyrene.
1	22 (withdrawn): A method for promoting cell or tissue growth at a desired site,
2	said method comprising contacting said site with a ligand-modified biopolymer in an amount
3	effective to promote cellular chemotaxis and cell or tissue growth at said site, wherein said
4	biopolymer component is a member selected from the group consisting of agarose, polylysine

PATENT

Appl. No. 10/815,468 Amdt. dated July 20, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1641

5	and polyacrylamide, wherein said ligand component is a chemotactic peptide specific for a cell
6	surface receptor, and wherein said ligand component is attached to said biopolymer component
7	via chemoselective ligation.
1	23 (withdrawn): The method of claim 22, wherein said biopolymer is agarose.
1	24 (withdrawn): The method of claim 22, wherein said site is a member selected
2	from the group consisting of a stent, a graft, an organ, a tissue and an implant.
1	25 (withdrawn): The method of claim 22, wherein said cell or tissue growth
2	occurs in vivo.
1	26 (withdrawn): The method of claim 22, wherein said cell or tissue growth
2	occurs in vitro.
1	27 (withdrawn): A method for assaying the binding of ligands to a binding
2	partner, said method comprising
3	(a) contacting a binding partner with a microarray of claim 1; and
4	(b) determining the amount of binding that occurs between said binding partner
5	and the ligands present in the discrete regions of said microarray.
1	28 (withdrawn): The method of claim 27, wherein said microarray comprises a
2	modified agarose biopolymer.
1	29 (currently amended): A microarray comprising a support having a plurality of
2	discrete regions having a preformed ligand-modified biopolymer spotted thereon, wherein the
3	ligand can be the same or different from a ligand in any other of said discrete regions, and
4	wherein the concentration of said ligand in said discrete regions varies less than 50% is
5	substantially normalized.
1	30 (currently amended): A microarray comprising a support having a plurality of
2	discrete regions made by

PATENT

Appl. No. 10/815,468 Amdt. dated July 20, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1641

(a) forming a ligand-modified biopolymer by attaching a ligand to a

functionalized biopolymer via chemoselective ligation; and

(b) spotting an aliquot of said modified biopolymer mixture onto each of a

plurality of discrete regions on a solid support wherein said ligand can be the same or different

from a ligand in any other of said discrete regions, and wherein the concentration of said ligand

in said discrete regions <u>varies less than 50%</u> is substantially normalized.